Search results for "STAGE"

showing 10 items of 1393 documents

Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance

2011

BACKGROUND: The aetiological factors of hepatocellular carcinoma may vary over time. AIMS: The study assessed the potential impact of the aetiological factors on the effectiveness of surveillance in real-world patients. METHODS: Multicentre, cross-sectional study enrolling consecutive hepatocellular carcinoma cases during a six month period. RESULTS: 1733 cases (1311 prevalent and 422 incident) were recruited (mean age 68.6 years; 46.1% cases over 70 years; 73.9% males; 95.3% with cirrhosis); 63.0% were hepatitis C virus positive and 23.7% were virus negative. Amongst incident HCCs, 34.5% were single ≤3cm and 54.4% met the Milan criteria; 61.6% were diagnosed during surveillance; virus nega…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularEpidemiologyHepatocellular carcinomaCross-sectional studyCancer stageCancer stage; Epidemiology; Hepatitis; Hepatocellular carcinoma; Surveillance; Age Distribution; Aged; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B Surface Antigens; Hepatitis C Antibodies; Humans; Incidence; Italy; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prevalence; Ultrasonography; Population Surveillance; Hepatology; GastroenterologyMilan criteriaHepatitisAge DistributionInternal medicineEpidemiologyPrevalenceCarcinomaHumansMedicineHCCAgedUltrasonographyHepatitisHepatitis B Surface AntigensSurveillanceHepatologybusiness.industryIncidenceIncidence (epidemiology)CarcinomaLiver NeoplasmsCancer stage Epidemiology Hepatitis Hepatocellular carcinoma SurveillanceGastroenterologyHepatocellularHepatitis C AntibodiesMiddle Agedmedicine.diseaseETIOLOGYSurgeryCross-Sectional StudiesLogistic ModelsItalyHepatitis C Virus PositivePopulation SurveillanceHepatocellular carcinomaMultivariate AnalysisSURBVEILLANCEFemalebusiness
researchProduct

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

2020

INTRODUCTION: Despite the negative impact of covert hepatic encephalopathy on the outcome of patients with liver cirrhosis, data regarding the ability of different testing strategies to predict overt hepatic encephalopathy (OHE) development and mortality are limited. This study aimed to compare the ability of Psychometric Hepatic Encephalopathy Score (PHES), critical flicker frequency (CFF), simplified animal naming test (S-ANT1), and clinical covert hepatic encephalopathy (CCHE) score to predict OHE development and mortality. METHODS: A total of 224 patients with liver cirrhosis were tested with different testing strategies and prospectively followed up regarding clinically relevant outcom…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationRisk AssessmentSeverity of Illness IndexArticleEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicinePredictive Value of TestsInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyHepatic encephalopathyAgedReceiver operating characteristicbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyFeasibility Studies030211 gastroenterology & hepatologyFemalebusinessFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data

2007

Several randomized controlled trials have compared a transjugular intrahepatic portosystemic shunt (TIPS) with large-volume paracentesis in cirrhotic patients with refractory ascites. Although all agree that TIPS reduces the recurrence rate of ascites, survival is controversial. The aim of this study was to compare the effects of TIPS and large-volume paracentesis in cirrhotic patients with refractory ascites by means of meta-analysis of individual patient data from 4 randomized controlled trials.The study population consisted of 305 patients: 149 allocated to TIPS and 156 to paracentesis. Cumulative probabilities of transplant-free survival and of hepatic encephalopathy (HE) were estimated…

Liver CirrhosisMalemedicine.medical_specialtymedicine.medical_treatmentKaplan-Meier EstimateGastroenterologySpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseHepatorenal syndromeRisk FactorsInternal medicineAscitesmedicineParacentesisHumansParacentesisHepatic encephalopathyAgedFirst episodeHepatologymedicine.diagnostic_testbusiness.industrySodiumGastroenterologyAscitesBilirubinPatient dataMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTreatment OutcomeMeta-analysisHepatic EncephalopathyRegression AnalysisFemaleRefractory ascitesPortasystemic Shunt Transjugular Intrahepaticmedicine.symptombusinessTransjugular intrahepatic portosystemic shuntGastroenterology
researchProduct

Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression

2021

Abstract Background The universal treatment of diagnosed patients with chronic HCV infection has been widely conducted in Italy since 2017. However, the pool of individuals diagnosed but yet to be treated in Italy has been estimated to end around 2025, leaving a significant proportion of infected individuals undiagnosed/without care. Estimates of this population are currently unknown. Methods A probabilistic modelling approach was applied to estimate annual historical HCV incident cases by their age-group (0–100 years) distribution from available literature and Italian National database (1952 to October 2019). Viraemic infection rates were modelled on the main infection routes in Italy: peo…

Liver CirrhosisPediatricsBlood transfusionEpidemiologymedicine.medical_treatmentlaw.invention0302 clinical medicineFibrosislawEpidemiologyPrevalence030212 general & internal medicineStage (cooking)ChildSubstance Abuse IntravenousMonte CarloAged 80 and overeducation.field_of_studyMiddle AgedHepatitis CInfectious DiseasesTransmission (mechanics)ItalyChild PreschoolHCVmedicine.symptomModels Theoretical: Young AdultHumanAdultmedicine.medical_specialtySexual transmissionAdolescentLiver Cirrhosi030231 tropical medicinePopulationMarkov chainAntiviral AgentsMicrobiologyAsymptomaticlcsh:Infectious and parasitic diseasesYoung Adult03 medical and health sciencesVirologymedicineHumanslcsh:RC109-216Hepatitis C infectioneducationAgedAntiviral Agentbusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornUndiagnosedInfantModels Theoreticalmedicine.diseaseParasitologybusiness
researchProduct

The association between education level and chronic liver disease of any etiology

2020

Abstract Background The potential link between educational level and chronic liver diseases (CLD) were explored using the mortality records of liver cirrhosis, which lack accuracy and are unable to identify the different etiological factors of liver cirrhosis. Information on the association of low educational level with the severity of CLD is lacking. Aim To evaluate the potential association linking education level to etiology and clinical stage of CLD cases. Methods Consecutive enrolment of 11,107 subjects with CLD aged≥18 years prospectively recruited in two national surveys in 2001 and 2014 at one of the participating Italian liver units throughout the country. Subjects were pooled in t…

Liver Cirrhosismedicine.medical_specialtyCirrhosisAlcohol DrinkingLiver CirrhosiDisease030204 cardiovascular system & hematologyEducational settingChronic liver diseaseLogistic regressionChronic disease03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineHBVInternal MedicinemedicineHumans030212 general & internal medicineStage (cooking)Association (psychology)Non-alcoholic Fatty Liver Disease.business.industryLiver DiseasesLiver DiseaseFatty liverMiddle Agedmedicine.diseaseItalyHCVEtiologyLiver disorderAlcoholbusinessHumanLiver disordersEuropean Journal of Internal Medicine
researchProduct

International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation.

2018

Nonalcoholic steatohepatitis (NASH)-related cirrhosis has become one of the most common indications for liver transplantation (LT), particularly in candidates older than 65 years. Typically, NASH candidates have concurrent obesity, metabolic, and cardiovascular risks, which directly impact patient evaluation and selection, waitlist morbidity and mortality, and eventually posttransplant outcomes. The purpose of these guidelines is to highlight specific features commonly observed in NASH candidates and strategies to optimize pretransplant evaluation and waitlist survival. More specifically, the working group addressed the following clinically relevant questions providing recommendations based…

Liver Cirrhosismedicine.medical_specialtyCirrhosisConsensusTime FactorsTissue and Organ ProcurementWaiting Listsmedicine.medical_treatmentConsensus Development Conferences as TopicBariatric SurgeryComorbidityLiver transplantationEnd Stage Liver DiseaseLiver diseaseNon-alcoholic Fatty Liver DiseaseDiabetes mellitusmedicineHumansObesityIntensive care medicineTransplantationbusiness.industrymedicine.diseaseComorbidityLiver TransplantationNatural historyTreatment OutcomeCardiovascular DiseasesEtiologybusinessDyslipidemiaTransplantation
researchProduct

Why do I treat my patients with mild hepatitis C?

2015

The major advances achieved in the treatment of HCV by the development of new direct-acting antiviral agents (DAAs) allow treatment of almost the entire spectrum of patients with chornic infection. As a result of the exceedingly high cost of DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis. Hence, treatment of patients with milder liver disease is often deferred. This could ultimately result in an increased burden of advanced liver disease and in increased long-term costs of management. Moreover, studies performed during the 'interferon era' and the early data on interferon-free regimens show that patients without severe fibro…

Liver Cirrhosismedicine.medical_specialtyCirrhosisGenotypeCost-Benefit AnalysisHepacivirusDiseaseAntiviral AgentsGastroenterologyVirological response03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineRibavirinHumansMedicine030212 general & internal medicineStage (cooking)Adverse effectHepatologybusiness.industryHcv clearanceInterferon-alphaHepatitis CHepatitis C Chronicmedicine.diseaseTreatment OutcomeImmunologyHCVDisease ProgressionDrug Therapy Combination030211 gastroenterology & hepatologybusiness
researchProduct

Beyond cure

2015

PURPOSE OF REVIEW The aim of this review was to define the implication of hepatitis C virus (HCV) eradication in patients with cirrhosis. RECENT FINDINGS Sustained virologic response (SVR) is associated with a favourable outcome in patients with cirrhosis especially in the presence of regression of cirrhosis but also with extrahepatic outcomes regarding health-related quality of life, risk of diabetes, risk of cardiovascular diseases and control of HIV replication by antiretroviral therapy. In patients with decompensated cirrhosis identifying the point of no return where viral eradication is not followed by clinical improvement is extremely relevant. A strict follow-up is needed in order to…

Liver Cirrhosismedicine.medical_specialtyCirrhosisHepatitis C virusImmunologymacromolecular substancesmedicine.disease_causeGastroenterologyEnd Stage Liver DiseaseQuality of lifeVirologyDiabetes mellitusInternal medicinemedicineHumansIn patientIntensive care medicineOncology (nursing)business.industryvirus diseasesEnd stage liver diseaseHematologyHepatitis C Chronicmedicine.diseasedigestive system diseasesInfectious DiseasesOncologyVirologic responseLiver dysfunctionbusinessCurrent Opinion in HIV and AIDS
researchProduct

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop

2011

Abstract The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild liver fibrosis and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the…

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularOrganophosphonateschronic hepatitis B The Italian recommendations for the therapy of hepatitis B Tenofovir Adefovir Cirrhosis Telbivudine Lamivudine Entecavirmedicine.disease_causeAntiviral Agentsadefovir; cirrhosis; entecavir; hbv; lamivudine; telbivudine; tenofovirHepatitis B ChronicInternal medicineTelbivudinemedicineAdefovirHBVHumansStage (cooking)TenofovirHepatitis B virusHepatologybusiness.industryAdenineLiver NeoplasmsGastroenterologyLamivudineEntecavirmedicine.diseaseVirologyItalyHepatocellular carcinomaReverse Transcriptase InhibitorsInterferonsbusinessmedicine.drug
researchProduct

Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.

2013

Background: Reversibility of advanced fibrosis after HCV-clearance is an important goal of therapy. Objectives: Measuring liver stiffness (LS) by transient elastography (TE) might be helpful in this setting. Patients and Methods: We evaluated 104 patients with biopsy-proven chronic hepatitis C (CHC) and sustained virological response (SVR) after Peg-Interferon (IFN) plus ribavirin since at least 18 months. HCV-eradication was confirmed searching for serum HCV-RNA (TMA® sensitivity > 5-10 IU/ml). Data from literature reported the best LS cut-off values for different stages of liver fibrosis were 7.1 kPa for Metavir stage 2 (F2), 9.5 kPa for F3 and 12.5 for cirrhosis (F4). Results: TE was not…

Liver Cirrhosismedicine.medical_specialtyPathologyCirrhosisGastroenterologychemistry.chemical_compoundFibrosisInternal medicineBiopsyMedicineStage (cooking)Hepatologymedicine.diagnostic_testbusiness.industryRibavirinmedicine.diseaseKowsarliver stiffnessInfectious DiseaseschemistryElasticity Imaging TechniquesSteatosisInsulin ResistancebusinessTransient elastographyResearch ArticleHepatitis monthly
researchProduct